International trends in oesophageal cancer survival by histological subtype between 1995 and 2014

Abstract

IntroductionSurvival from oesophageal cancer remains poor, even across high-income countries. Ongoing changes in the epidemiology of the disease highlight the need for survival assessments by its two main histological subtypes, adenocarcinoma (AC) and squamous cell carcinoma (SCC).MethodsThe ICBP SURVMARK-2 project, a platform for international comparisons of cancer survival, collected cases of oesophageal cancer diagnosed 1995 to 2014, followed until 31st December 2015, from cancer registries covering seven participating countries with similar access to healthcare (Australia, Canada, Denmark, Ireland, New Zealand, Norway and the UK). 1-year and 3-year age-standardised net survival alongside incidence rates were calculated by country, subtype, sex, age group and period of diagnosis.Results111 894 cases of AC and 73 408 cases of SCC were included in the analysis. Marked improvements in survival were observed over the 20-year period in each country, particularly for AC, younger age groups and 1 year after diagnosis. Survival was consistently higher for both subtypes in Australia and Ireland followed by Norway, Denmark, New Zealand, the UK and Canada. During 2010 to 2014, survival was higher for AC compared with SCC, with 1-year survival ranging from 46.9% (Canada) to 54.4% (Ireland) for AC and 39.6% (Denmark) to 53.1% (Australia) for SCC.ConclusionMarked improvements in both oesophageal AC and SCC survival suggest advances in treatment. Less marked improvements 3 years after diagnosis, among older age groups and patients with SCC, highlight the need for further advances in early detection and treatment of oesophageal cancer alongside primary prevention to reduce the overall burden from the disease.

RNA m6A demethylase FTO-mediated epigenetic up-regulation of LINC00022 promotes tumorigenesis in esophageal squamous cell carcinoma

“…However, the annual global mortality rate of ESCA remained the sixth in cancer-induced death in the past decade [ 1 , 5 ]. The 5-year survival rate for patients with advanced ESCA remains dismal, due to uncontrolled tumor growth and relapse and unknown molecular mechanisms [ 6 – 8 ]. In the past few decades, considerable efforts have been made to investigate the molecular mechanisms underlying ESCC pathogenesis [ 9 , 10 ].…”

Antisense lncRNA NNT-AS1 Promoted Esophageal Squamous Cell Carcinoma Progression by Regulating Its Sense Gene NNT Expression

“…2×10 3 transfected cells were planted in 96-well plate per well. At different checking points (0, 24, 48, 72, and 96h), the cells were incubated in complete medium with 20µL MTT (concentration: 0.5 mg/mL) for 4 h. Then, the medium was removed and DMSO (150 µL per well) was added to dilute the formazan that formed from MTT.…”

“…Esophageal cancer incidence ranks the seventh of all malignancies, with mortality ranking the sixth [1,2]. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (ESAD) account for the major histological subtypes of esophageal cancer [3]. ESCC has a particularly high incidence in eastern Asia, eastern and southern Africa [4].…”

A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma

“…Despite advances in surgical and oncological management, the prognosis of patients with oesophageal adenocarcinoma (OAC) remains poor 1 . The incidence of OAC is rising in the Western world 2 , but the majority of patients still present with advanced disease and palliation is the only treatment available to them.…”